Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz, M
Right arrow Articles by Cruz, S
Right arrow Search for Related Content
PubMed
Right arrow Articles by Diaz, M
Right arrow Articles by Cruz, S

Chest, Vol 100, 682-684, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Itraconazole in the treatment of coccidioidomycosis

M Diaz, R Puente, LA de Hoyos and S Cruz
Pulmonary Service, University Hospital, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.

Sixteen patients with coccidioidomycosis were treated with itraconazole for one year. Sixteen suffered from pulmonary coccidioidomycosis, two of them had associated mediastinal lesions, and one suffered from skin coccidioidomycosis. The daily dose used was 400 mg during the one-year period. Patients were clinically evaluated every month and tested for mycosis every three months. All patients except for one showed negative cultures on the third month after treatment began. Effectiveness achieved was excellent in eight patients (50 percent); a very good response was found in seven patients (44 percent); no response was seen in one patient (6 percent). There were four (25 percent) relapses and one dropout. Side effects seen were high blood pressure (19 percent) and lower limb edema (6 percent), which was temporary and at no time required discontinuing the drug therapy. We believe that itraconazole is an effective drug to treat coccidioidomycosis with a wide safety margin. It is well tolerated, and the incidence of relapses was low.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
J. N. Galgiani, A. Catanzaro, G. A. Cloud, R. H. Johnson, P. L. Williams, L. F. Mirels, F. Nassar, J. E. Lutz, D. A. Stevens, P. K. Sharkey, et al.
Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis: A Randomized, Double-Blind Trial
Ann Intern Med, November 7, 2000; 133(9): 676 - 686.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Lortholary, D. W. Denning, and B. Dupont
Endemic mycoses: a treatment update
J. Antimicrob. Chemother., March 1, 1999; 43(3): 321 - 331.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. N. Galgiani
Coccidioidomycosis: A Regional Disease of National Importance: Rethinking Approaches for Control
Ann Intern Med, February 16, 1999; 130(4_Part_1): 293 - 300.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.